Verrica Q1 FY26 net loss flat at $9.7 million; revenue rises 46.1% YoY to $5 million

• Verrica Pharmaceuticals posted Q1 2026 net loss of $9.7 million, or $0.45 per share, versus net loss of $9.7 million, or $1.03 per share, a year earlier.
• Revenue climbed 46.1% year over year to $5 million, including U.S. YCANTH net product revenue of $4.3 million, up 25.4% year over year.
• YCANTH dispensed applicator units rose 51.3% year over year to 15,302, up 12.1% sequentially, passing 100,000 total units since launch.
• License and collaboration revenue was $733,000, driven primarily by commercial supply for partner Torii Pharmaceutical’s YCANTH launch in Japan.
• Management said it has surpassed 50% of current targeted enrollment in Phase 3 COVE-2 common warts trial, expecting to initiate second Phase 3 trial COVE-3 in mid-2026 with sites in US and Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121601PRIMZONEFULLFEED9718590) on May 12, 2026, and is solely responsible for the information contained therein.